Schizophrenia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Participants with a diagnosis of schizophrenia according to DSM-5 criteria 2.Clinically stable participants. Clinically stable is defined as having had no delusions or hallucinations and no significant deterioration in motivation during the six months prior to participation in the study. Any medication is acceptable for participation in this study. 3.Participants with sufficient Japanese language ability 4.Participants who have been fully briefed on the study, fully understood, and have given their voluntary written consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1.Participants with a history of neurological disease with organic abnormalities in the central nervous system 2.Participants with serious cardiovascular, respiratory, gastrointestinal, renal, endocrine, or other diseases 3.Participants with co-morbidities related to visual and hearing impairments 4.Participants who are deemed by the principal investigator to be unsuitable as research subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery after 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Schizophrenia Cognition Rating Scale (SCoRS) Specific Level of Functioning Assessment(SLOF) Positive and Negative Syndrome Scale (PANSS) Amplitude of auditory mismatch negativity Gamma activity during auditory steady state response (ASSR) paradigm | — |
Countries
Japan
Contacts
Graduate school of Medicine. Hokkaido University Department pf Psychiatry